MetCura Pharmaceuticals AUS

MetCura Pharmaceuticals AUS Pty Ltd is a company dedicated to developing products for the treatment of Acinetobacter baumannii infections. Its product, APL-2301, is a novel antibacterial drug with a unique mechanism of action independently developed by the company, intended for treating infections caused by Acinetobacter baumannii. The planned clinical trial in Australia will be the first-in-human Phase I clinical trial for APL-2301.